Clinical Trial

NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06741150
Lead Sponsor Newish Technology (Beijing) Co., Ltd.
Conditions Intraepithelial Neoplasia, Cervical Cancer
Enrollment 18 participants
Start Date 2024-06-24
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-18